Abstract
Overview
Introduction
Unmet needs across the cancer market remain high, with most therapies
conferring low levels of specificity and high toxicity. Therapeutic cancer
vaccines offer an attractive therapeutic addition, delivering treatment of
high specificity, low toxicity and prolonged activity. However, despite years
of R&D, a reproducible survival benefit has proved elusive, leaving the market
wide open.
Scope
- Research and analysis of the cancer vaccines pipeline with in-depth
clinical and commercial assessment of Phase III candidates, plus expert opinion
- Seven major pharmaceutical market sales forecasts to 2015 for key pipeline
candidates incorporating product specific assumptions and events
- Segmentation and examination of product pipeline by phase, technology
platform, vaccine specificity, indication and developer
- Insight and analysis of clinical, regulatory, pharmacoeconomic and
strategic issues that challenge the path to commercialization of a cancer
vaccine
Highlights
105 different pipeline cancer vaccines have been identified of which 14 are in
late-phase development. These existing candidates have a forecast sales
potential of up to $3.1 billion in the seven major pharmaceutical markets by
2015.
Despite Dendreon' s Provenge preregistration status, skepticism still surrounds
the use of dendritic cells as a viable technology platform. Indeed, an
entirely new set of clinical and strategic issues has been brought to light
across the spectrum of cancer vaccine development classes.
While personalized immunotherapies offer greater levels of specificity and
lower toxicity, generalized alternatives should facilitate production, help
achieve economies of scale and offer broader utility in a range of tumor
types. It is therefore not suspiring that these ' off-the-shelf' products
dominate the current pipeline.
Reasons to Purchase
- Acquire a detailed appreciation and impartial perspective of the entire
cancer vaccine developmental pipeline
- Identify the key therapeutic cancer vaccines in late-phase development
based on sales forecasts to 2015 and drug assessment methodology
- Consider, assess and react to opportunities and risks for cancer vaccines
within the oncology market
| 
View Cart
